Fifthly, our analysis solely focused on the impact of efruxifermin on liver fibrosis, while its effects on other aspects, such as glycemic control, insulin sensitivity, lipid metabolism, and weight changes, were not evaluated. Here, INS is linked to Hepatic fibrosis.